JP2016518328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518328A5 JP2016518328A5 JP2016501667A JP2016501667A JP2016518328A5 JP 2016518328 A5 JP2016518328 A5 JP 2016518328A5 JP 2016501667 A JP2016501667 A JP 2016501667A JP 2016501667 A JP2016501667 A JP 2016501667A JP 2016518328 A5 JP2016518328 A5 JP 2016518328A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- alkoxy
- alkyl
- gene
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 230000004927 fusion Effects 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 8
- -1 amino, hydroxyl Chemical group 0.000 claims 7
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 101150039757 EIF3E gene Proteins 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 102100033132 Eukaryotic translation initiation factor 3 subunit E Human genes 0.000 claims 2
- 101000591201 Homo sapiens Receptor-type tyrosine-protein phosphatase kappa Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 101150109344 Ptprk gene Proteins 0.000 claims 2
- 102100034089 Receptor-type tyrosine-protein phosphatase kappa Human genes 0.000 claims 2
- 101150116752 Rspo3 gene Proteins 0.000 claims 2
- 101100279491 Schizosaccharomyces pombe (strain 972 / ATCC 24843) int6 gene Proteins 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361777427P | 2013-03-12 | 2013-03-12 | |
| US61/777,427 | 2013-03-12 | ||
| PCT/US2014/024885 WO2014165232A1 (en) | 2013-03-12 | 2014-03-12 | Compounds for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016518328A JP2016518328A (ja) | 2016-06-23 |
| JP2016518328A5 true JP2016518328A5 (cg-RX-API-DMAC7.html) | 2017-04-13 |
Family
ID=51659101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501667A Pending JP2016518328A (ja) | 2013-03-12 | 2014-03-12 | 癌治療のための化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9713612B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2968348A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2016518328A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20150125665A (cg-RX-API-DMAC7.html) |
| CN (1) | CN105142641A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014248568B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2905830C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014165232A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2173379E (pt) | 2007-07-02 | 2015-11-24 | Oncomed Pharm Inc | Composições e métodos para o tratamento e diagnóstico de cancro |
| EP2731625B1 (en) | 2011-07-15 | 2018-04-18 | OncoMed Pharmaceuticals, Inc. | Rspo binding agents and uses thereof |
| KR101824300B1 (ko) * | 2012-06-15 | 2018-01-31 | 큐어제닉스 인크. | Wnt 신호전달 억제제로서 화합물, 조성물, 및 그의 용도 |
| CN104854132A (zh) | 2012-07-13 | 2015-08-19 | 昂考梅德药品有限公司 | Rspo3结合剂及其用途 |
| KR20150125665A (ko) | 2013-03-12 | 2015-11-09 | 큐어제닉스 인크. | 암 치료용 화합물 |
| CN105348298B (zh) * | 2014-07-04 | 2019-03-19 | 沈阳中化农药化工研发有限公司 | 取代芳基吡啶类化合物及其用途 |
| MA40574A (fr) | 2014-09-16 | 2016-03-24 | Oncomed Pharm Inc | Traitement de maladies fibrotiques |
| MA41123A (fr) * | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | Polythérapie pour le traitement du cancer |
| AU2016267142B2 (en) * | 2015-05-26 | 2020-12-24 | Curegenix Corporation | Tumor biomarkers and use thereof |
| CN115554399A (zh) * | 2015-05-31 | 2023-01-03 | 源生公司 | 用于免疫疗法的组合组合物 |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| CN105254613A (zh) * | 2015-10-08 | 2016-01-20 | 苏州云轩医药科技有限公司 | 具有Wnt信号通路抑制活性的杂环化合物及其应用 |
| WO2017062688A1 (en) * | 2015-10-08 | 2017-04-13 | Suzhou Yunxuan Yiyao Keji Youxian Gongsi | Wnt signaling pathway inhibitors and therapeutic applications thereof |
| EP3359154B1 (en) * | 2015-10-08 | 2021-05-26 | Suzhou Yunxuan Yiyao Keji Youxian Gongsi | Wnt signaling pathway inhibitors and therapeutic applications thereof |
| WO2017095918A2 (en) * | 2015-12-01 | 2017-06-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer using rspo3 antagonists |
| WO2017162611A1 (en) * | 2016-03-21 | 2017-09-28 | Astrazeneca Ab | Quinoline-3-carboxamide compounds and their use in treating cancer |
| WO2017167150A1 (zh) * | 2016-03-31 | 2017-10-05 | 苏州云轩医药科技有限公司 | 一种3-氟吡啶杂环化合物及其应用 |
| EP3541957B1 (en) | 2016-11-21 | 2025-06-25 | Bruker Spatial Biology, Inc. | A method for sequencing nucleic acids |
| JP7419068B2 (ja) * | 2016-12-21 | 2024-01-22 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 悪性腫瘍を特定するためのキット及びその使用 |
| CA3052492A1 (en) * | 2017-03-30 | 2018-10-04 | F.Hoffmann-La Roche Ag | Naphthyridines as inhibitors of hpk1 |
| CN107441045B (zh) | 2017-07-21 | 2018-10-19 | 广州源生医药科技有限公司 | 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法 |
| KR102717600B1 (ko) | 2017-10-06 | 2024-10-15 | 포르마 세라퓨틱스 인크. | 유비퀴틴 특이적 펩티다제 30의 억제 |
| JP7525402B2 (ja) | 2018-05-14 | 2024-07-30 | ナノストリング テクノロジーズ，インコーポレイティド | 化学的組成物とそれを利用する方法 |
| CA3098628A1 (en) | 2018-05-17 | 2019-11-21 | Forma Therapeutics, Inc. | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors |
| CN108685923A (zh) * | 2018-06-07 | 2018-10-23 | 广州源生医药科技有限公司 | Wnt信号通路抑制剂在治疗LGR5阳性癌症中的应用 |
| US10961534B2 (en) | 2018-07-13 | 2021-03-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating porphyria |
| PT3860989T (pt) | 2018-10-05 | 2023-06-30 | Forma Therapeutics Inc | Pirrolinas fundidas que atuam como inibidores da protease 30 específica da ubiquitina (usp30) |
| US12365686B2 (en) * | 2019-07-08 | 2025-07-22 | Jiangsu Kanion Pharmaceutical Co., Ltd. | Compound as porcupine inhibitor and use thereof |
| CN117088875A (zh) * | 2020-10-28 | 2023-11-21 | 杭州阿诺生物医药科技有限公司 | 一种高活性Wnt通路抑制剂化合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9298098A (en) * | 1997-09-03 | 1999-03-22 | Guilford Pharmaceuticals Inc. | Amino-substituted compounds, methods, and compositions for inhibiting parp activity |
| ATE552253T1 (de) * | 2002-11-08 | 2012-04-15 | Novartis Int Pharm Ltd | 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren |
| DK1673475T3 (da) | 2003-10-10 | 2010-07-19 | Deutsches Krebsforsch | Sammensætninger til diagnose og terapi af sygdomme, som er forbundet med aberrant ekspression af futriner (R-Spondiner) og/eller Wnt |
| WO2005120509A1 (en) | 2004-06-04 | 2005-12-22 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| CA2593578C (en) * | 2005-01-07 | 2013-11-05 | Emory University | Cxcr4 antagonists for the treatment of medical disorders |
| WO2008086462A2 (en) | 2007-01-11 | 2008-07-17 | Wyeth | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| CN102573473B (zh) | 2009-06-09 | 2015-05-27 | 加利福尼亚资本权益有限责任公司 | 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物 |
| CN102558173B (zh) | 2010-12-31 | 2015-05-20 | 广州源生医药科技有限公司 | 抑制wnt信号传导的化合物、组合物及其应用 |
| AU2013226323B2 (en) | 2012-02-28 | 2016-07-14 | Irm Llc | Cancer patient selection for administration of Wnt signaling inhibitors using RNF43 mutation status |
| KR101824300B1 (ko) | 2012-06-15 | 2018-01-31 | 큐어제닉스 인크. | Wnt 신호전달 억제제로서 화합물, 조성물, 및 그의 용도 |
| KR20150125665A (ko) | 2013-03-12 | 2015-11-09 | 큐어제닉스 인크. | 암 치료용 화합물 |
| AU2016267142B2 (en) | 2015-05-26 | 2020-12-24 | Curegenix Corporation | Tumor biomarkers and use thereof |
-
2014
- 2014-03-12 KR KR1020157024496A patent/KR20150125665A/ko not_active Withdrawn
- 2014-03-12 CN CN201480013734.1A patent/CN105142641A/zh active Pending
- 2014-03-12 US US14/772,337 patent/US9713612B2/en active Active
- 2014-03-12 CA CA2905830A patent/CA2905830C/en active Active
- 2014-03-12 WO PCT/US2014/024885 patent/WO2014165232A1/en not_active Ceased
- 2014-03-12 EP EP14778108.2A patent/EP2968348A4/en not_active Withdrawn
- 2014-03-12 JP JP2016501667A patent/JP2016518328A/ja active Pending
- 2014-03-12 AU AU2014248568A patent/AU2014248568B2/en not_active Ceased
-
2017
- 2017-06-08 US US15/617,988 patent/US10238652B2/en active Active
-
2019
- 2019-01-29 US US16/261,353 patent/US10660889B2/en active Active